Psychedelic businesses risk repeating the cannabis industry's mistakes as regulation, investor pressure, and market concentration threaten access and equity

Psychedelic businesses face a cannabis-style trap in which early idealism gives way to heavy regulation, investor-driven scaling, and market concentration that can sideline smaller operators and restrict equitable access. Commercialization pressures can push the field toward expensive compliance models, intellectual property races, and limited participation by communities that helped sustain psychedelic knowledge and practice. Cannabis offers a cautionary parallel because legalization often favored well-capitalized firms while taxes, licensing barriers, and fragmented rules squeezed independent participants and kept illicit markets alive. Similar dynamics in psychedelics could shape therapy access, product development, and clinic ownership before broader public benefit is secured. Policy design matters because rules set now can determine whether psychedelic ecosystems remain diverse, affordable, and community-rooted or become dominated by a narrow group of corporate winners.